Prostate Cancer | Specialty

Dr. Hwang on the Utility of Antiandrogens in Metastatic Prostate Cancer

April 14th 2020

Clara Hwang, MD, discusses the utility of antiandrogens in patients with metastatic prostate cancer.

High BMI, Weight Gain Tied to Increased Mortality in Prostate Cancer

April 13th 2020

Obese men with nonmetastatic prostate cancer have higher cardiovascular disease–related mortality and all-cause mortality, and potentially increased prostate cancer–specific mortality.

Early Intensification With Apalutamide Is Key in Metastatic Castration-Sensitive Prostate Cancer

April 13th 2020

Neeraj Agarwal, MD, discusses the implications of the PFS2 data from the TITAN trial in metastatic castration-sensitive prostate cancer.

PSMA-Targeted Radionuclide Therapy Shows Preliminary Activity in mCRPC

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.

Dr. Tagawa on Targeting PSMA in Prostate Cancer

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Dr. Armstrong on the Utility of Pamiparib and Other PARP Inhibitors in Prostate Cancer

April 10th 2020

Andrew J. Armstrong, MD, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.

Dr. Antonarakis on Trial Examining Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

April 9th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Dr. Agarwal on PFS2 Data From the TITAN Trial in mCSPC

April 9th 2020

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Dr. McKay on the Utility of Radium-223 in the Treatment of mCRPC

April 9th 2020

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

Dr. Beltran on the Utility of Liquid Biopsies Versus Tissue Biopsies in CRPC-NE

April 8th 2020

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

Dr. Oh on the Role of Radiopharmaceuticals in mCRPC

April 8th 2020

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer

April 7th 2020

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

Dr. Fendler on Rationale for Creating the 68Ga-PSMA-11 PET in Prostate Cancer

April 4th 2020

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC

April 3rd 2020

A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.

Dr. Gomella on Potential Impact of Targeted Therapy Approvals on Genetic Testing in Prostate Cancer

April 3rd 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Novel Hormonal Agents Foster New Approaches in Nonmetastatic CRPC

April 1st 2020

Nonmetastatic castration-resistant prostate cancer is a more recently defined clinical state of prostate cancer, for which several approved drugs are now available.

PARP Investigations Continue on Path Toward Precision Medicine in Prostate Cancer

March 31st 2020

The use of PARP inhibitors against DNA damage repair alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field.

Ep. 14: Emerging Agents in the Management of Prostate Cancer

March 31st 2020

Ep. 13: Avoiding Repeat Lines of AR-Targeted Therapy in mCRPC

March 31st 2020

Ep. 12: What is Radium 223

March 31st 2020